Stereochemistry | MIXED |
Molecular Formula | C18H23NO3.ClH |
Molecular Weight | 337.841 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(CCC1=CC=C(O)C=C1)NCC(O)C2=CC=C(O)C=C2
InChI
InChIKey=JHGSLSLUFMZUMK-UHFFFAOYSA-N
InChI=1S/C18H23NO3.ClH/c1-13(2-3-14-4-8-16(20)9-5-14)19-12-18(22)15-6-10-17(21)11-7-15;/h4-11,13,18-22H,2-3,12H2,1H3;1H
Molecular Formula | C18H23NO3 |
Molecular Weight | 301.3801 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Ractopamine is a feed additive to promote leanness in animals raised for their meat. Pharmacologically, it is a TAAR1 agonist and β adrenoreceptor agonist that stimulates β1 and β2 adrenergic receptors. Ractopamine is known to increase the rate of weight gain, improve feed efficiency, and increase carcass leanness in finishing swine. Its use in finishing swine yields about three kilograms of additional lean pork and improves feed efficiency by 10%. Ractopamine is the active ingredient in products known as Paylean for swine and Optaflexx for cattle, developed by Elanco Animal Health, a division of Eli Lilly and Company, for use in food animals for growth promotion. Ractopamine use has been banned in most countries, including the European Union, mainland China and Russia while 27 other countries, such as Japan, the United States, Canada, and South Korea, have deemed meat from livestock fed ractopamine safe for human consumption. Ractopamine is safe for finishing pigs heavier than 240 lb (110 kg) when administered in the diet at concentrations up to 10 ppm and fed for up to 35 days.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
180.0 nM [Ki] | |||
6.97 null [pKd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Patents
Sample Use Guides
Ractopamine used in the dose range of 4.5 to 18.0 g/ton
Route of Administration:
Oral
CHO-K1 cells were grown to confluence in 24-well plates. The medium was removed and the cells were pre-labelled with [3H]-adenine by incubation for 2 h with 2 mCi/mL [3H]-adenine in serumfree medium (0.5 mL per well). The [3H]-adenine was removed, and each well was washed by the addition and removal of 1 mL serum-free medium. Then, 1 mL serum-free medium containing 1 mM IBMX was added to each well, and the cells were incubated for 15 min. Ractopamine (in 10 mL serum-free medium) was added to each well, and the plates were incubated for 10 min–5 h. The reaction was terminated by the addition of 50 mL concentrated HCl per well. The plates were then frozen, thawed and [3H]-cAMP separated from other 3H-nucleotides by sequential Dowex and alumina column chromatography